Homepage
Author:
Citius Oncology, Inc.
Posted Date:
March 31, 2026
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Citius Oncology, Inc.
March 31, 2026
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology, Inc.
March 24, 2026
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Citius Oncology, Inc.
March 10, 2026
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
Citius Oncology, Inc.
March 4, 2026
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
Citius Oncology, Inc.
February 13, 2026
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
Citius Oncology, Inc.
February 12, 2026
